Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Revenues:      
Product sales $ 4,157 $ 76  
Product royalty revenues 1,406 3,407 $ 1,773
Research and development reimbursements 909 12,712 2,783
Contract revenue 41,759 22,749 6,800
Total revenues 48,231 38,944 11,356
Cost of sales 8,101 4,939 2,082
Expenses:      
Research and development 20,624 34,285 53,327
Selling, general and administrative 54,685 38,460 12,349
Total expenses 75,309 72,745 65,676
Loss from operations (35,179) (38,740) (56,402)
Interest expense, net (2,518) (2,016) (903)
Derivative (loss) gain   (13,167) 121
Other income (expense), net 25 (295) (210)
Net loss $ (37,672) $ (54,218) $ (57,394)
Basic and diluted loss per share $ (0.72) $ (1.12) $ (1.51)
Weighted average common stock shares outstanding, basic and diluted 52,384,876 48,355,200 37,941,044